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Abstract: Over the past decades, chronic sleep reduction and a concurrent development of obesity have been recognized 
as a common problem in the industrialized world. Among its numerous untoward effects, there is a possibility that insom-
nia is also a major contributor to obesity. This attribution poses a problem for caffeine, an inexpensive, “natural” agent 
that is purported to improve a number of conditions and is often indicated in a long-term pharmacotherapy in the context 
of weight management. The present study used the “common target” approach by exploring the tentative shared molecular 
networks of insomnia and adiposity. It discusses caffeine targets beyond those associated with adenosine signaling   
machinery, phosphodiesterases, and calcium release channels. Here, we provide a view suggesting that caffeine could  
exert some of its effects by acting on several signaling complexes composed of HIF-1/VEGF/IL-8 along with NO, TNF-
, IL1, and GHRH, among others. Although the relevance of these targets to the reported therapeutic effects of caffeine 
has remained difficult to assess, the utilization of caffeine efficacies and potencies recommend its repurposing for   
development of novel therapeutic approaches. Among indications mentioned, are neuroprotective, nootropic, antioxidant, 
proliferative, anti-fibrotic, and anti-angiogenic that appear under a variety of dissimilar diagnostic labels comorbid with 
obesity. In the absence of safe and efficacious antiobesity agents, caffeine remains an attractive adjuvant.  
Keywords: Caffeine targets, obesity, reactive oxygen species, networks, polypharmacy.  
INTRODUCTION 
  Obesity prevalence has visibly increased over the recent 
decades to the point where its spread was dramatized by a 
comparison with an epidemic. With a long list of its comor-
bidities, it has become a burden at the individual, familial, 
and societal levels. The word ‘obesity’ itself is a recognized 
synecdoche, a figure of speech in which the whole may   
stand for a part; a particular cause (e.g., hyperphagic   
obesity), appearance problem, local expansion of adiposity 
(e.g. visceral obesity), or “obesity-related diseases” [1], for 
which only individually tailored medical solutions could be 
entertained.  
  In what might appear as an effort of an ‘environmental 
reductionism’, a progressive decrease in nightly sleep time is 
now suggested to be a catalyst of obesity [2-5]. Chronic 
sleep shortage that in the last decades afflicts at least one-
third of the population in the industrialized world [6] has 
become a novel bastion of the obesogenic “environment” 
and is now listed among the contributors to the visceral form 
of obesity that underlies the metabolic syndrome [7-9]. In-
somnia is a recalcitrant therapeutic problem. Therefore, with 
numerous other paths to obesity [10], designing a highly 
innovative drug that produces all the expected therapeutic 
effects by targeting a particular ‘common mechanism’ [11] 
seems unrealistic. In efforts to reduce costs, health profes-
sionals are turning to novel information on the mode of   
action of inexpensive old drugs. In a sobering revelation of  
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Allen Roses, then with GlaxoSmithKline (cited in [12]), 
fewer than half of the patients prescribed some of the most 
expensive drugs actually derived any benefit from them. 
With this authoritative assessment of a leader in applied 
pharmacogenetics, our choice is to review here the benefits 
of an old and inexpensive agent, such as caffeine that is an 
integral part of a normal everyday routine.  
BACK TO AN OLD PARADIGM  
  Adiposity, much as insomnia(s) might be conceived of as 
“pseudopathology”. This paleopathological term in Craw-
ford’s language [13] means a quasi-normal phenomenon in 
the sense that both are useful adaptations that are no longer 
essential and could be (but not necessarily are) harmful. Be-
cause of a significant degree of overlap that exists between 
normal and aberrant, pseudopathology represents a recalci-
trant research problem. Unwittingly, insomnia-obesity cou-
pling creates a significant therapeutic problem because caf-
feine, a member of the methylxanthine family of drugs 
(1,3,7-trimethylxanthine) and the oldest of the socially en-
dorsed addictive psychostimulants, is also employed to com-
bat food craving and weight gain. The figures of the United 
States National Coffee Association (cited in [14]) indicate 
that over 50% of adult Americans drink coffee every day, 
mostly as a “caffeine fix” or as a “pick-me-up” morning rit-
ual. With a daily load of at least 4 mg/kg per regular coffee 
drinker in the US, and twice that in Scandinavia [15], caf-
feine consumption was rightfully named an ‘epidemic’, that 
is suggestively parallel to that of obesity. The flagrant irony 
here is that a reputed somnolytic is used to curb weight gain 
that could be attributed inter alia to insomnia.  
  A recent review [16] restated a familiar admonition that 
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sleep, could induce subtle and physiologically meaningful 
changes in the sleep EEG, in particular in the self-rated caf-
feine-sensitive subjects. In reality, we do not know who may 
be vulnerable to weight gain following sleep deprivation and 
whether those categorized as being “sensitive to caffeine” in 
one domain would manifest a similar responsiveness to it in 
other conditions. Sleep is the latest addition to the list of the 
obesogenic factors. While its social plausibility is appealing, 
the role of insomnia in obesity is not compelling. Insomnia 
or better said, insomnias appear in dissimilar profiles and 
severity and are confounded by the standard of living, age, 
overall health status [17, 18], as well as by numerous meth-
odological problems of their analysis [9]. A recent study by 
Lauderdale et al. [19] found no evidence that sleep duration 
influences gaining weight over the span of 5 years. Adeno-
sine is an endogenous somnogen, and the central effect of 
caffeine is believed to act via the antagonism of adenosine 
receptors (A1, A2A, A2B, and A3, subsequently as ADORA1, 
ADORA2A, ADORA2B, and ADORA3). Ever since the 
influential review by Snyder and Sklar [20], caffeine has 
been perceived as a “magic” nonselective antagonist of 
ADORA1 and ADORA2A. That view had steered much of 
the neurobiological research and was used as a thread to 
guide further studies [21, 22]. The question is whether the 
somnolytic effects disqualify caffeine as a potential anti-
obesity medicine. Not necessarily.  
MINING CAFFEINE TARGETS  
  Caffeine affects diverse bodily tasks and can thus be   
affected by multiple physiologic variables that are almost 
impossible to take into account. In order to reduce the com-
plexity of the expected target display, we employed a com-
mercially available engine for drug target identification and 
recording their interaction, Ingenuity Pathway Analysis 
(IPA) [23]. Fig. (1) provides a summary of ‘caffeine neigh-
borhood’ compiled using IPA.8. In it, caffeine molecule ap-
pears as a hub that establishes connections by crossing the 
boundaries of other intrinsic modules, thereby creating a 
temporary ‘parasitic’ unit. Such drug hubs were termed 
elsewhere ‘pharmodules’ [24]. The point of this distinction is 
in the fleeting character of such sub-networks that gradually 
disappear with a half-life determined by the drug elimination 
or that of its metabolites.  
  Predictably, caffeine node is connected to the adenosine 
receptors, as well as several molecules, via the shortest paths 
that do not instruct us about the orthogonal somnolytic and 
weight gain effects (Fig. (2)). One might expect that its som-
nolytic effects implicate diverse neurotransmitter systems, 
which agonists and antagonists are on the current agenda of 
the pharmaceutical industry [25]. Among them, only 
tachykinin precursor 1 (TAC1) may be of interest. TAC1 is a 
member of tachykinin family of peptides that is widely dis-
tributed in the central, peripheral, and enteric nervous sys-
tems of many species. It was implicated in modulation of 
many behavioral and physiological functions including emo-
tional behaviors. Recently, TAC1 was also recognized as a 
novel antiobesity target. A selective antagonist of TAC1 
receptor, (CJ012,255;  Pfizer, New York, NY) given par-
enterally was reported to prevent weight gain in lean mice 
placed for 2 weeks on high-fat, whereas similar treatment of 
genetically obese mice resulted in weight loss and reduced 
adiposity, along with an improved insulin sensitivity [26]. 
The role of TAC1 in sleep is still uncertain. It may cause 
central alertness and insomnia [27]. Yet when microinjected 
bilaterally into a sleep-promoting region in the preoptic area, 
it rather appears to promote sleep [28]. Neurokinin 1 recep-
tor antagonist casopitant is under development by GlaxoS-
mithKline (GSK-679769) as an antidepressant, anxiolytic, 
and hypnotic/sedative [25].  
  The effect of caffeine via TAC1 may be more complex 
because it increases activation of tumor necrosis factor- 
(TNF-). However, in vitro study of human adipose tissue 
obtained after abdominal dermolipectomy showed a strong 
and dose-dependent down-regulation of TNF- expression in 
both adipocyte and stromavascular fraction cells, whereas 
interleukin-6 (IL-6) was only down regulated in the latter 
cells [29]. That is an interesting result, particularly for adi-
posity developed in the elderly, as IL-6 gene knockouts were 
noticed to manifest ‘mature-onset’ obesity [30]. Thus, by 
decreasing the expression of proinflammatory cytokine TNF-
, caffeine could quench the inflammatory potential of adi-
pose tissue [29, 31, 32].  
  Several other cytokines affected by caffeine could influ-
ence the EEG parameters, albeit after local neocortical appli-
cation (reviewed in [33]). For example, growth hormone 
(GH)-releasing hormone (GHRH) applied in small doses to 
the surface of the rat somatosensory cortex, decreased the 
EEG delta waves on that side, while higher doses enhanced 
the delta power. Similar to its microinjection into the preop-
tic anterior hypothalamus, GHRH enhanced the EEG delta 
power and duration of the non-REM periods in a state   
dependent manner, i.e., it occurred during non-REM state 
but not during REM sleep [34]. Caffeine in concentrations 
that are relevant to human consumption had little or no effect 
on IL-1, whereas TNF- production was suppressed in all 
individuals studied [31].  
  Other molecules of functional relevance could only be 
revealed  via IPA path analysis with an extra or a ‘linker’ 
node. Such hitherto unexplored targets are hypocretin/orexin 
neuropeptides that are distributed to the majority of cell 
groups that regulate behavioral arousal. Consequently, their 
depletion might lead to sleep aberration akin to narcolepsy. 
One study, found the adenosine-mediated inhibition of the 
firing of hypocretin/orexin neurons without a change in their 
membrane potential. The inhibitory effect of adenosine was 
dose dependent and mediated by ADORA1 [35]. Caffeine 
did not activate this system. However, some clusters of 
ADORA1 heteromerize with ADORA2A receptors into the 
ADORA1-ADORA2A heteromer. This entity could lead to 
opposite read-outs of chemical signals in the system. For 
example, in this way, caffeine produces the opposite effects 
on glutamate release at low and high concentrations of syn-
aptic adenosine ([36, 37] and references therein).  
  An unexpected second-tier entity in the network was 
melatonin (MEL). Caffeine was reported to induce a pro-
longed nocturnal rise in pineal MEL, an endogenous regula-
tor of circadian rhythms of several biological functions, in-
cluding sleep-wake cycles in humans and other mammals 
[38]. In a study by Härter et al. [39], caffeine (200 mg) co-Winning a Won Game  Current Neuropharmacology, 2010, Vol. 8, No. 2    151 
administered with oral MEL increased its bioavailability by 
142% on average. This may be a clinically relevant augmen-
tation, given that in humans MEL bioavailability is poor 
[40]. In another study in humans, evening caffeine at a dose 
corresponding to two ordinary cups of coffee was reported to 
augment the nocturnal serum MEL levels [41].  
  MEL is able to affect the regulation of body mass and 
energy balance via leptin (LEP). MEL-supplemented mice 
had significantly higher plasma LEP levels than control mice 
[42]. LEP is an anorectic hormone produced in adipose cells. 
Treatment with LEP was shown to significantly decrease 
























Fig. (1). Caffeine pharmodule relationships with nodes and hubs of other networks assembled using IPA 8.0 (www.ingenuity.com). Nodes 
stand for any biological entity capable of functional interaction, such as genes, proteins, receptors or small molecules. The connections can 
be undirected or directed (arcs) that signify any relationships between the nodes listed in IPA connectivity menu (e.g. co-expression, physical 
interaction, phosphorylation, co-localization, etc). Each hub is connected by edges with diverse distant systems. To simplify the graph such 
connections and interconnections were eliminated. Abbreviations: ADORA1-adenosine A1 receptor; ADORA3-adenosine A3 receptor; 
ADORA2A-adenosine A2a receptor; ADORA2B-adenosine A2b receptor; ADRB2-adrenergic, beta-2 receptor; BDNF-brain-derived   
neurotrophic factor; cAMP-cyclic AMP; CYP1A2, CYP1B1-cytochrome P450; DA-dopamine; DRD2-dopamine receptor D2; HIF1A-
hypoxia inducible factor 1, alpha subunit; IL1/IL6/TNF--IL1B-interleukin 1, beta; Pde-Phosphodiesterase; PPARG-peroxisome proliferator-
activated receptor ; Ryr- Ryanodine receptor; TAC1-tachykinin. 152    Current Neuropharmacology, 2010, Vol. 8, No. 2  Myslobodsky and Eldan 
and blunt the treadmill running-induced elevation in plasma 
levels of corticosterone [43]. MEL receptors are widely   
distributed in diverse tissues, such as epithelial cells, liver, 
intestine, kidney, immune cells, including adipocytes, i.e., 
the cells that synthesize LEP [44], such that the sedative   
effects of LEP may be as relevant as the ingestion control 
implemented  via  MEL. Regardless of the sleep-promoting 
efficacy of MEL, it may be an interesting, and hitherto unex-
plored, anti-obesity agent. Preclinically, MEL proved to re-
duce body mass in diet-induced obesity in Sprague Dawley 
rats [45, 46]. Again in preclinical studies, MEL as well as its 
novel agonist NEU-P11, inhibited body weight gains, depos-
its of abdominal fat and metabolic profiles in obese rats with 
no influence on food intake [47].  
  The circulating LEP plasma values are increased at night 
in rodents and in humans [48, 49] although the strength of 
the effect, and even its presence, varies as a function of   
glucose and insulin levels and body mass. Male ob/ob mice, 
a genetic model of impaired LEP production that results in 
severe obesity along with symptoms of metabolic dysregula-
tion, showed sleep fragmentation and the elevated number of 
arousals from sleep [50]. Acute LEP administration altered 
sleep architecture in normally fed rats. It decreased REM 
sleep by about 30% and somewhat increased non-REM sleep 
time (by 13%), mostly in the delta-frequency band (a com-
mon EEG marker of sleep intensity). These effects, too, were 
coupled with energy status and were absent in conditions of 
















Fig. (2). Auto-layout of ‘Caffeine (C) neighborhood’ based on Ingenuity curated finding (IPA, Ingenuity® Systems). The nature of 
interaction although available in the database or incorporated in labels of edges/arcs, was stripped from graphs to reduce the clutter, save for 
an example of maximal motif NF-B-TAC1-TNF isolated on the right (see text for explanations). In the latter case, and in the rest of the 
nodes, self-connections were removed. The type of interaction is only identified as either ‘direct’ or ‘indirect’ (dashed lines stand for indirect 
interactions; solid lines indicate direct interactions). The various shapes of nodes denote the functional class of the molecules that are easily 
understood from their abbreviations. In order to reduce the clutter, molecular interactions that appear unrelated to the effect were trimmed. 
Additional molecules of interest were simply inserted by entering their terms into IPA search engine one by one or using multiple terms 
searches and endorsing all desirable information on connections in the ‘New pathway’ (or any available stored pathway) window via com-
mands, such as ‘connect,’ or ‘path analysis’ based on PubMed data. Path analysis is based on network property known as node ‘between-
ness’; the number of shortest paths between any chosen nodes. The latter is the smallest number of steps between any arbitrarily chosen 
nodes in the network selected for analysis. When there were several shortest paths between the nodes, the first one was selected as better 
substantiated by literature. These commands permitted to manually edit networks and in this way to create custom molecular pathways sup-
ported by the current experimental literature evidence. Color-coding depicts multiple roles that molecules may play in several signaling 
pathways. Arbitrarily selected are: Apoptosis of endothelial cells (p=1.41E-12); ROS production (p=5.11E-11); Energy expenditure 
(p=4.16E-14); and Thermoregulation (p=2.34E-15. More than four functions would make the graph more confusing in the chosen format. 
The probability that each biological function assigned to the set of molecules is due to chance alone was determined using Fischer’s exact 
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  Recent studies imposing nocturnal-life style on adult vol-
unteer students reported a simultaneous decrease in MEL 
and LEP levels [51]. The style of diet was virtually identical 
to the pattern of eating imposed during the month of Ra-
madan. In this Moslem holiday, food intake is restricted to 
the night hours, thereby causing sleep delay. Ramadan fast-
ing diminished a peak in nocturnal MEL consequent to 
modifications in sleep schedule [52]. A study conducted by 
the same group five years later exposed significant shifts of 5 
h 30 min in peak and trough serum LEP levels on the 
twenty-third day of Ramadan [53].  
  The simultaneous attenuation of the nocturnal increase in 
LEP and MEL is reminiscent of that observed in patients 
with night-eating syndrome [54]. A delayed food intake 
caused disrupted circadian patterns of several hormones by 
causing phase delays of LEP and insulin (INS), as well as in 
the circadian MEL rhythm. The circulating levels of ghrelin, 
the primary orexigenic hormone was phase advanced by 5.2 
h. Their amplitudes were also blunted, save for the increased 
thyroid-stimulating hormone (TSH) amplitude [54]. The 
LEP-MEL coupling is a complex process that is apparently 
determined by a number of metabolic participants [51]. In 
vitro analysis, using isolated rat adipocytes incubated with 
MEL (1 nM) and INS, did not affect LEP expression when 
administered alone, whereas administered together they have 
increased it by 120%. A synthetic glucocorticoid dexametha-
sone showed meager effects on LEP. However, when added 
simultaneously with MEL, LEP release was increased by a 
robust 250% [44]. 
  A recent study found no significant differences in LEP 
levels in chronic insomnia patients as compared to healthy 
control men [55]. However, control individuals were 
matched for body weight with insomnia patients so that the 
relevance of this finding to insomnia-induced obesity is 
questionable. As though emphasizing this contention, stage 4 
in normal subjects was shorter when compared to those with 
insomnia.  
CAFFEINE IN OBESITY SYNDEMIC 
  Obesity scatters an array of molecules that in different 
combinations are implicated in inflammation, angiogenesis, 
cellular proliferation, and cellular injury [56]. Among   
the latter are reactive oxygen species (ROS), a group of   
O
2 molecules in different states of oxidation or reduction, 
as well as further-derived reactive species, such as hydrogen 
peroxide and hypochlorous acid. The etiology of several 
human ailments is attributed to cellular damage induced by 
ROS.  
  ROS are important components in the vicious cycle trig-
gered by adiposity because they are believed to modulate the 
adipogenesis. The term describes the course of mesenchymal 
stem cells (preadipocytes) commitment, their proliferation, 
differentiation into mature fat (adipocytes), and their hyper-
trophy. More specifically, ROS accelerate the rate of evolu-
tion of preadipocytes into the mature lipid-laden adipocytes, 
which are the predominant source of pro-inflammatory adi-
pokines [57]. By comparison, smaller young adipocytes ca-
pable of proliferation act as ‘metabolic buffers’ that avidly 
absorb fatty acids in the postprandial period [58-60]. A fail-
ure to store excess lipid in adipocytes via hyperplasia will 
inevitably channel fatty acids into non-adipose tissues [61, 
62], thereby fueling low-grade inflammation and conse-
quently leading to metabolic syndrome [63, 64]. As an effec-
tive scavenger of hydroxyl radicals and singlet oxygen, caf-
feine may be helpful when the endogenous antioxidants, 
such as glutathione and the enzyme superoxide dismutase are 
depleted [65].  
  The potential therapeutic role of caffeine in obesity may 
be in controlling angiogenesis. Angiogenesis is the process 
of formation of new vessels from preexisting structures of 
endothelial and vascular supporting cells (reviewed in [66, 
67]). The mechanisms by which new vascular network is 
created has yet to be worked out. Adipose tissue is capable 
of self-maintenance by its intrinsic angiogenic potency [68] 
that assures supply of oxygen and nutrients and a removal of 
waste products. A seminal hypothesis of tumor growth pro-
posed by Folkman [69] prompted the idea that visceral fat 
expands in a manner of malignant cells, by recruiting 
neovascularization in order to mitigate hypoxia. Growth of 
solid tumors is a multistage process that begins with an avas-
cular stage followed by a vascular phase, which depends on 
the induction of angiogenic factors VEGF and IL-8.  
  Adenosine appears capable of a massive stimulation of 
angiogenesis by acting as a “survival hormone” essential for 
adaptation during hypoxia, neuronal trauma, response to 
different kinds of stressors, as well as cellular workload [70, 
71]. It rises 100-fold during periods of oxygen depletion and 
ischemia [72] and conspires with hypoxia in rapidly deploy-
ing neoangiogenesis. The most fascinating aspect of this 
process is that it triggers an evolutionarily conserved path-
way governed by the hypoxia-induced factor-1 (HIF-1) [73]. 
The presence of HIF-1 is a key catalyst and regulator of the 
delivery of oxygen, because it induces several angiogenic 
factors identified thus far, such as vascular endothelial 
growth factors (VEGFs), interleukin-8 (IL-8) and others([74] 
for review and references therein). The VEGF family in hu-
mans currently comprises several members, namely, VEGF-
A, VEGF-B, VEGF-C, VEGF-D, erythropoietin (EPO), pla-
cental growth factor (PGF) and a novel regulatory factor, 
fibroblast growth factors (FGF) [75]. Some of them are illus-
trated in Fig. (2). VEGF-A is a particularly interesting iso-
form of the VEGF family [76] that has received attention for 
its increase of the vascularization needed for the expansion 
of adipose tissue [77]. It creates a destabilized network with 
disorganized, leaky, immature, and unstable vessels [74]. 
That is how omentum-induced angiogenesis could be facili-
tated [78] under hypoxic conditions. Caffeine antagonizes 
the up-regulation of factor-1 (HIF-1) along with VEGF, and 
IL-8.  
  Anti-angiogenesis agents are considered a viable treat-
ment option in malignancies [79]. Likewise, the VEGF sys-
tem may represent a profitable target for the pharmacological 
treatment of obesity. For example, bevacizumab, a recombi-
nant humanized monoclonal antibody to VEGF was tested 
recently in preclinical animal models. It caused loss of 
weight and anorexia as a side effect of therapy [80]. It cannot 
be recommended off-label for obesity in view of the fact that 
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elevated blood pressure in patients treated with anti-
angiogenesis agents is not well understood, mechanistically, 
it may be attributed to the existing deficit in the form of cap-
illary dropout (rarefaction) [81-83]. Patients with hyperten-
sion have reduced microvascular density, with some evi-
dence supporting a primary role for rarefaction in causing 
hypertension. Although rarefaction may be present in nor-
motensive persons, revealingly, they have a family history  
of hypertension [84]. Compared with lean subjects, over-
weight/obese individuals appear to have 44% lower capillary 
density and 58% lower VEGF, suggesting that rarefaction 
could drive obesity via hypoxia and inflammation [85].  
  Caffeine might be a better choice for targeting the signal-
ing cascade of angiogenesis. It was suggested to be a promis-
ing therapeutic agent with a direct impact on neovasculariza-
tion of human tumors via VEGF inhibition [86]. Even oral 
administration of green tea (Camellia sinensis) has been no-
ticed to inhibit the formation and growth of several tumor 
types in animal models [87]. VEGF up-regulation was abro-
gated by caffeine. It reduced by an impressive 46% the 
neovascularization in a mouse ischemic hind limb model 
[88]. To what extent caffeine is a functionally relevant agent 
to affect transmural pressure and vasomotion in mechani-
cally altered leaky vessels is difficult to predict [89]. How-
ever, it promises to curb mechanically triggered neointimal 
hyperplasia. In this way, it can mitigate a major cause of 
morbidity following stent deployment in patients with coro-
nary artery disease [90]. This is an important effect, as 
healthy individuals with mild obesity, ischemia, insomnia, 
and inflammation may be exposed to hypoxia during a long-
term stay at moderate altitude (> 1700 m), e.g. when skiing. 
Fortunately, in skiers and hikers only EPO was elevated, 
whereas VEGF levels remained unchanged. In keeping with 
this result, post-altitude examinations at 7-10 days and 6-7 
weeks showed that body fat has actually decreased during 
the study [91].  
  More devastating episodes of hypoxia are experienced by 
patients afflicted by obstructive sleep apnea [56, 92, 93]. 
Caffeine is not considered for therapeutic intervention in 
apnea, perhaps in fear of further increasing sympathetic out-
flow, blood pressure, and ultimately increasing the frequency 
of awakenings. But perhaps, apnea may not always have to 
be aggressively treated. In a study of comorbidities associ-
ated with moderate sleep apnea in the elderly, Lavie and 
Lavie [94] obtained reduced mortality risk, indicating that 
cellular stress of apnea could bring to the pathophysiological 
forefront some molecular circuits responsible for ‘hormetic’ 
or ‘preconditioning’ effects [95, 96]. This ‘apnea paradox’ 
cautions that the taxonomically driven drug indications may 
need to be revisited. More than 60% of patients with obstruc-
tive sleep apnea represent a heterogeneous category of indi-
viduals who are devoid of the expected nocturnal fall in 
blood pressure (defined as ‘non-dippers’) independent of 
obesity [97], so that they may be afflicted by a peculiar vas-
cular dysregulation. Blunted reduction of nocturnal blood 
pressure (operationally defined as fall of systolic and dia-
stolic blood pressure <10%) was associated with higher lev-
els of high-sensitivity C-reactive protein [98], a marker of 
inflammation associated with increased cardiovascular mor-
bidity. Would they benefit from ingesting coffee? A study of 
982 diabetic and 1,058 non diabetic women without cardio-
vascular disease from the Nurses’ Health Study may provide 
a tentative answer. These women who drank   4  cups of 
coffee a day obtained favorable metabolic effects including 
decreased insulin resistance, decreased incidence of type 2 
diabetes, and lower levels of markers of inflammation. The 
effect is believed to partly operate through increased serum 
adiponectin levels [99].  
  The sufferers of chronic sleep apnea commonly manifest 
polycythemia, a state of abnormally increased circulating red 
blood cells that is associated with the significantly higher 
serum levels of VEGF [100]. Given that VEGF plays a key 
role in the angiogenic response, caffeine may be an agent of 
choice in polycythemia, as well. Oddly, those with poly-
cythemic state are noticed to ingest increased quantities of 
caffeine-containing beverages [101]. The only hypothetical 
impediment of caffeine ingestion might be in its abrupt dis-
continuation with no support of lifestyle changes in indi-
viduals with intrinsically hypovascular adiposity. It is possi-
ble to speculate that similar to what happens in secondarily 
avascular and hypoxic tumors [66], a wave of angiogenesis 
prompted by VEGF accumulation may rebound in weight 
gain.  
  A higher average daily caffeine intake was noticed to 
improve the cognitive performance in patients with moder-
ate/severe sleep apnea [102]. This is in keeping with the abil-
ity of caffeine to strengthen a long-term memory formation 
by activating cortical neural oscillators via glutamate release 
from nerve terminals [103], as reflected in hippocampal 
gamma oscillations. The latter are an EEG frequency range 
associated with the cognitive functions that is suppressed 
during hypoxia [104]. In neuropsychiatry, obesity is dis-
cussed among modifiable factors of age-associated memory 
impairment that may also herald Alzheimer’s dementia [105] 
when caffeine may be counted among other memory en-
hancers. In a recent study in rats given 25 mg/kg pentyle-
netetrazol (a seizure-producing agent known to cause retro-
grade amnesia) or ethanol, caffeine (5 mg/kg) canceled etha-
nol-induced retrograde amnesia in a new odor-recognition 
test [106]. It is of interest that a combination of a phosphodi-
esterase-5 inhibitor and an adenosine ADORA2A antagonist, 
mimicking two major mechanisms of action of caffeine, pre-
vented the memory impairment, though neither drug alone 
had such effect.  
  As an inhibitor of phosphodiesterase-5, a key enzyme in 
the biochemical pathway mediating erection, caffeine may 
inspire a practitioner to try it off-label as benign aid in erec-
tile dysfunctions, inasmuch as these are a common complica-
tion of obesity and associated with it diabetes mellitus and 
insulin-resistance [107]. Preclinically, an 8-week administra-
tion of caffeine improved the erectile function in diabetic rats 
by inhibiting phosphodiesterases and thus up-regulating cav-
ernous intracellular cyclic guanosine monophosphate [108]. 
Caffeine may be of benefit in other androgen dysfunctions 
associated with obesity, such as oligozoospermia and a re-
duced spermatozoa motility count [109]. The latter were 
noticed to be associated with increased BMI [110].  
  The account may continue into peripheral neuropathol-
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from abnormalities of the VIII cranial nerve. Among other 
factors, obesity along with chronic hyperglycemia may be 
implicated in the early sensorineural hearing loss [111]. Pre-
clinically, coffee consumption was shown to facilitate recov-
ery from diabetes-induced auditory neuropathy in diabetic 
mice [112]. Finally, psoriasis, a chronic inflammatory skin 
disease, as well as psoriatic arthritis, are common among 
obesity comorbidities [113]. A double-blind, placebo-
controlled study proved that topical application of 10% caf-
feine appears to be an effective, safe and inexpensive treat-
ment for the stable plaque psoriasis [114].  
  In sum, this admittedly selected sample suggests that 
caffeine might be a useful agent to handle a range of condi-
tions associated with obesity, if only we knew how to use it 
more profitably outside of the “Starbuck” coffeehouses. That 
leads to the next point.  
“REPURPOSING” OF CAFFEINE 
  An interesting feature of caffeine is its ability to enhance 
the efficacy of co-administered agents without compromis-
ing their safety. Caffeine co-administration with aspirin was 
noticed to cause long-lasting hyperactivity [115]. Combining 
caffeine (10 mg/kg) with a low amount of alcohol (‘caffei-
nol’ [116]) appears to reduce the cortical infarct volume and 
improves recovery following stroke. In a model of rotating 
rodent (‘hemiparkinsonian mice’), daily co-administration of 
caffeine to L-DOPA produced enhanced rotational behavior, 
i.e., a promising feature to think of the non-dopaminergic 
augmentation in the treatment of Parkinson's disease [117].  
  Adding caffeine to ephedrine has produced a noticeable 
weight reduction, whereas either drug given alone yielded 
effects similar to those achieved in the placebo group [118]. 
A cross-sectional population-based telephone survey of 
9,403 adults revealed that an estimated 20.6% of women and 
9.7% of man used a weight-loss supplement containing caf-
feine (with other stimulants such as ephedra) [119, 120]. 
Patients with hypothalamic obesity who had been steadily 
gaining weight benefited clinically from a regimen of caf-
feine and ephedrine [121]. In one trial, a “caffeine+” design 
was used with nicotine in order to amplify anorectic effects 
of the latter [122]. In addition, it has a range of time effects 
that regulate the body fat stores from millisecond that are 
relevant for changing satiety, to setting a stage for a lasting 
reduction in food intake via sympathetic activity control and 
plasticity changes via glutamate [123]. Caffeine pairing with 
novel flavors appears to raise their subjective predilection as 
compared to liking of the novel flavors paired with a placebo 
[124], thereby suggesting that, oddly enough, caffeine may 
enhance the common underlying neurobiological and psy-
chological mechanisms of desire. It is long known that caf-
feine has adjuvant pain-relieving properties in some cases, 
even though it is not clear why analgesia may not appear in 
others [125, 126]. 
  These co-administered drugs are so diverse that clearly 
no common molecular denominator for their combinations is 
currently in sight. For example, preclinical studies in the rat 
inoculated with osteosarcoma exposed a striking enhance-
ment by caffeine of the cytocidal effects of platinum-based 
anticancer drug cisplatin. The extent of tumor inhibition was 
closely correlated with the average plasma concentration of 
caffeine [127]. Likewise, adding caffeine to standard chemo-
therapy enhanced the antitumor response rates in patients 
with osteosarcoma. On the median follow-up period of 72 
months, it extended event-free survival in all patients to 
76%, whereas an overall survival reached 100% [128]. Caf-
feine has also been reported to modulate directly or indi-
rectly the effect of antitumor agents, so as to greatly sensitize 
tumor cells to genotoxic stress and thus aid in cancer chemo-
prevention [86]. Chronic exposure to caffeine prior to the 
appearance of the palpable mammary tumors significantly 
reduced both the tumor burden and the metastatic coloniza-
tion [129].  
  All considered, caffeine has an adequate record of safety 
in long-term ingestion [130, 131] (see, however, [132]); for 
adopting it for a diversity of “orphan” conditions based on 
emerging needs. This transgression of nosological indica-
tions is a novel trend in the current climate of dwindling 
health care resources and rising costs of drug development 
[133]. Most commonly, it appears in the form of a pragmatic 
ad-hoc off-label prescription on physician’s initiative that 
ultimately, may be institutionalized as a drug “repurposing” 
or drug “repositioning” [134, 135]. A review by Ashburn and 
Thor [136] makes an admirable exhibit of several appealing 
Cinderella stories illustrating an ‘indication switch’. One of 
them is a miraculous comeback of thalidomide that after its 
tragic fall has now numerous indications. Among thalido-
mide’s parallel biographies is a discovery of its anti-
angiogenic properties that has made it a candidate drug in 
oncology. As mentioned above, caffeine could acquire a par-
allel resume by improving the clinical outcome in patients 
with malignancy [86, 129]. Moreover, it taps into a deeper 
need to reconsider an antiquated practice (and legislation) 
based on nosological indications in favor of ‘fixing’ a par-
ticular pathophysiological aberration that is shared by several 
disease entities.  
  However, before caffeine attracts attention of the phar-
maceutical and biotech companies, its appeal for “repurpos-
ing” has to be prepared by network analysis. Visualizing the 
drug-target landscapes would pave the way for future de-
signs. By detailing molecular targets and links that otherwise 
might be overlooked, caffeine pharmodule could evolve into 
a decision-making tool by providing effective filters for con-
sidering the role of age, gender, race, and comorbidities 
[137] when designing a promiscuous agent for a particular 
disease state. An important feature of drug interactions in 
networks is that their connections are ‘weighted’ because 
formally, a number (‘weight’) can be assigned to each edge 
(Fig. (2); insert). In order to illustrate its meaning, a triad 
NF-B-TAC1-TNF is isolated on the right along with all the 
interactions between each of its members labeled next to the 
edges. As analyzed elsewhere [138], each node of the set is a 
participant in more than one biochemical reaction (e.g., acti-
vation, inhibition, biochemical modification, protein-protein 
interaction, transcription, translocation, and other). Conse-
quently, each two neighbors of “functional motifs” may be 
active in a variety of ways at different conditions because its 
edges indicate that they could become functionally engaged  
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determined by the common roles in a particular ‘pharmod-
ule’, rather than the presence of certain structural or pharma-
cophoric features. That is, they belong to the mutual ‘bio-
space’, regardless of whether they share binding properties 
and thus are also united in the same ‘chemospace’ [139]. 
Therefore, the orientation of the arcs cannot reflect the 
course of information flow in network, i.e., it cannot confi-
dently predict the sequence of responses to a drug in phar-
module. Although IPA provides an efficient and powerful 
means for mining of drug action and disease mechanism 
relationships it has yet to include adequate formalism for 
such predictions to be modeled.  
ON WINNING A WON GAME: THERAPEUTIC   
IMPLICATIONS AND CAVEATS 
  Management of obesity is torn between two opposite 
tendencies: pharmacotherapy and lifestyle changes. Due to 
its modest efficacy and side effects, the pharmacotherapy of 
obesity is hoped to effect a cure chiefly when it is weaved 
into environmental changes. Caffeine is an example of an 
‘ergogenic/metabolic perspective’ slanted in the direction of 
reducing adiposity in people with a “low-energy-output phe-
notype” [140].  
  In a symmetric concession, therapeutic virtues of the per-
sonal responsibility in controlling appetite and lifestyle are 
believed to be boosted by the future antiobesity drugs [141]. 
These drugs would not control an epidemic of weight gain, 
and realistically, practicing physicians are busy dealing with 
a catalog of diverse co-morbidities of obesity [142]. In this 
regard, obesity is truly a “syndemic” rather than an epidemic. 
The term “syndemic” was coined in the early 90ies by the 
anthropologist Merrill Singer (reviewed in [143]) to empha-
size the role of environmental factors in the context of their 
synergistic relations with some major afflictions. The ‘up-
grading’ of an epidemic into the syndemic implies the need 
for novel drug targets that are capable of handling numerous 
chronic comorbidities along with those causing the ‘core’ 
affliction.  
  Caffeine might evolve into such a drug. Its broad-
spectrum therapeutic potential includes lipolytic, neuropro-
tective, nootropic, antioxidant, proliferative, anti-fibrotic, 
anti-angiogenic, and anti-diabetic effects [70]. Why then   
is formal position in the pharmacotherapy so insignificant. 
Perhaps, to paraphrase the famous line of Frank Marshall, 
“The hardest thing in pharmacology is to win a won game”. 
By prevailing in its social acceptance as a common drink, 
caffeine has lost in prestige and its potential medicinal ap-
peal has declined; its pharmacological research has become 
peripheral and academically unrewarding. Nonetheless, a 
demand for the ‘maximization of a drug value’ in the current 
pharmaceutical market [11, 135], seems to make it an attrac-
tive candidate for a “repurposing” program.  
  There are some problems on this path. Caffeine could 
modulate clinical phenotypes by interacting with several 
signal transduction pathways and becoming their temporary 
member. As network analysis revealed (Fig. (2)), some tenta-
tive caffeine targets cluster as though to suggest the need to 
influence the functionality of the group at once and in a pre-
dictable sequence. For example, HIF-1 and VEGF are acti-
vated  via  ADORA3A, whereas IL-8 is recruited via  the 
ADORA2B subtype. That permitted to specify the set of 
HIF-1/VEGF/IL-8 as a collective target in the context of 
tumor hypoxia for the development of the new antitumor 
drugs [144]. Inhibition of the extracellular signal-regulated 
kinase 1/2 (ERK1/2), p38, and Akt might be seen as still 
another complex caffeine target [144]. Further, by inhibition 
of the transcription nuclear factor kappa B (NF-B), caffeine 
could be linked to a range of processes, from the initiation of 
tumorigenesis to cell survival, suppression of cell prolifera-
tion, and plasticity [145-147]. In a similar way, induction in 
the NF-B protein by IL1 and TNF- stimulates the produc-
tion of NO and adenosine [33]. It is possible that insomnia 
increases the adenosine levels in bodily tissues via NF-B 
and along with NO, TNF-, IL1, and GHRH modulates the 
duration and intensity of non-REM sleep [148].  
  In caffeine repurposing, a persistent recommendation to 
limit caffeine ingestion by those who may be at risk of re-
duced bone mineral density [149], particularly in post-
menopausal women may need to be addressed. How impor-
tant is it to curb caffeine ingestion in this age group has yet 
to be determined, but here is a tentative example. In the past, 
fluoride was prescribed precisely for the fear of fractures 
associated with the reduction of bone volume. A Cochrane 
review showed that fluoride did improve the bone density as 
expected, but ‘paradoxically’ rather increased the risk of a 
non-vertebral fracture [150]. An explanation of the outcome 
may not be so paradoxical, because the increased bone den-
sity was obtained at the price of its diminished elasticity. 
Interestingly, bones of aged rats on a diet supplemented with 
caffeine (2 mg/100 g body weight), showed inferior me-
chanical properties except for the modulus of elasticity 
[151]. 
  Recently, the caffeine consumption was found to be sig-
nificantly and independently associated with suicidal acts in 
patients with bipolar disorder [152]. It is possibly the only 
agent to cause a withdrawal headache under placebo-
controlled double-blind conditions [153]. Its indications may 
need to be monitored even in obesity cases. Consider a small 
fat deposit around the heart (‘epicardial adipose tissue’). It 
was recently suggested to have health benefits by modulating 
the state of coronary arteries and myocardium through 
paracrine and direct secretion of pro and anti-inflammatory 
adipokines, including increased adiponectin production 
([154] and references therein). It may well act as a local anti-
inflammatory signal by inhibiting the NF-B protein and 
consequently, IL-6 and TNF- expression. In addition, as 
Iacobellis’ group proposed, epicardial adipocytes may 
sponge excessively high circulating levels of fatty acids and 
thus serve as a local energy source for myocardium in times 
of high demand.  
  Some aspects of the caffeine pharmacological profile are 
consistent with its antagonistic or perhaps, reverse agonistic 
effects at GABAA and/or benzodiazepine sites [155]. Unex-
pectedly, caffeine increased [
35S] TBPS binding (a standard 
test of increased ability to generate Cl
- currents). The latter is 
known to be directly related to the increased GABAergic 
neurotransmission [155]. This promiscuity of caffeine should 
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paradoxically, its proconvulsant efficacy might antagonize 
the experimental wave-spike discharges [156]. A similarly 
suggestive effect of caffeine was obtained in a study with a 
developmental model of epilepsy. In the latter, repeated 
postnatal administration of caffeine to rats (10 and 20mg/kg 
s.c. daily from P7 to P11) was challenged at days P18- and 
P25 with metrazol, in order to induce a spike-wave activity 
(a common model of human absences). Caffeine showed 
significant anticonvulsant effects at P18, but not in 25-day-
old animals. Neither the EEG nor the incidence and the pat-
tern of minimal clonic seizures changed with added dose of 
the convulsant. Some younger animals in both control age 
groups exhibited a transition to generalized tonic-clonic sei-
zures, yet no similar seizures were elicited in caffeine-
pretreated 25-day-old animals [157].  
  To summarize, off-label prescribing is only a minor part 
of the program. In order to achieve a greater goal of expand-
ing the potential of caffeine efficacy, it may need to be com-
bined with some complementary agents into a single pill, 
thereby creating a drug with new therapeutic properties. Ad-
ditionally, caffeine utility may be further enhanced by de-
signing its analogues with greater selectivity for the major 
classes of adenosine receptors [22]. That would conceivably 
require some supporting pharmacokinetic, pharmacody-
namic, and toxicology information for the FDA approval of  
a new indication. How soon this hope actually bears fruit 
remains to be seen.  
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